Arvinas ARVN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Program-specific external expense by Product | ||||||
| ARV-102 | $5.5M-3.5% | $5.7M+14.0% | $5M+31.6% | $3.8M-41.5% | $6.5M+18.2% | |
| ARV-393 | $3.7M+8.8% | $3.4M+30.8% | $2.6M+4.0% | $2.5M-3.8% | $2.6M+18.2% | |
| ARV-806 | $6.5M+12.1% | $5.8M+13.7% | $5.1M+200% | $1.7M+88.9% | $900K-25.0% | |
| Bavdegalutamide (ARV-110) | $200K-50.0% | $400K+33.3% | $300K-66.7% | $900K-18.2% | $1.1M-35.3% | |
| Other programs | $2.6M+52.9% | $1.7M+467% | $300K-62.5% | $800K-52.9% | $1.7M— | |
| Vepdegestrant ARV-471 | $8.9M-4.3% | $9.3M-34.5% | $14.2M-6.0% | $15.1M-37.3% | $24.1M+84.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arvinas break its business down?
- Arvinas (ARVN) reports program-specific external expense by product across 6 parts — ARV-102, ARV-393, ARV-806, Bavdegalutamide (ARV-110) and Other programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Arvinas's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arvinas's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
